Osteopetrosis is a genetic condition of increased bone mass, which is caused by defects in
osteoclast formation and function. Both autosomal recessive and autosomal dominant forms …

Osteonecrosis of the jaw (ONJ) was defined as exposed, necrotic bone in the maxillofacial
region for at least 8 weeks in patients receiving an antiresorptive medication for primary or …

Skeletal homeostasis relies upon a fine tuning of osteoclast (OCL)‐mediated bone
resorption and osteoblast (OBL)‐dependent bone formation. This balance is unsettled by …

Management of osteonecrosis of the jaw associated with antiresorptive agents is
challenging, and outcomes are unpredictable. The severity of disease is the main guide to …

Objective The most debated topic about medication-related osteonecrosis of the jaws
(MRONJ) is its therapy, as there are no definitive guidelines. The aims of this systematic …

Medication-related osteonecrosis of the jaw (MRONJ) is defined by the American
Association of Oral and Maxillofacial Surgeons (AAOMS) as the presence of an exposed …

It is now 40 years since bisphosphonates (BPs) were first used in the clinic. So, it is timely to
provide a brief review of what we have learned about these agents in bone disease. BPs are …

Bone is one of the most preferred sites of metastasis in lung cancer. Currently,
bisphosphonates and denosumab are major agents for controlling tumor-associated skeletal …

Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography
(PET/CT) is increasingly used in the initial staging, evaluation of treatment response, and …

Bisphosphonates are inhibitors of osteoclastic bone resorption with therapeutic benefit in a
variety of bone disorders in both adults and children. While these agents have been …